Dietary Polysaccharides in the Management of Inflammatory Bowel Disease: Recent Advances

Why It Matters

By targeting the gut microbiome, polysaccharide‑based interventions offer a non‑pharmacologic strategy to control IBD flare‑ups, potentially reducing reliance on steroids and biologics. This positions functional foods and nutraceuticals as emerging therapeutic assets in gastroenterology markets.

Key Takeaways

• Gastrodia elata polysaccharides boost Bifidobacterium and reduce pathogenic Shigella
• Oat β‑glucan increases SCFAs and strengthens tight‑junction proteins
• Lycium barbarum polysaccharides raise IgA and promote Lactobacillus growth
• SCFA elevation correlates with lower IL‑1β, TNF‑α, and IL‑6
• Polysaccharide therapy restores microbial diversity measured by Shannon index

Pulse Analysis

Inflammatory bowel disease remains a major clinical challenge, with dysbiosis and impaired barrier function driving chronic inflammation. While biologics have transformed care, they carry high costs and safety concerns, prompting interest in microbiome‑centric approaches. Dietary polysaccharides—complex carbohydrates found in grains, fruits, and medicinal herbs—act as selective substrates for gut microbes, positioning them as natural prebiotics that can recalibrate the intestinal ecosystem.

Mechanistically, polysaccharides foster the growth of commensal taxa such as Bifidobacterium, Lactobacillus, and Akkermansia, while curbing opportunistic pathogens like Shigella and Escherichia. This microbial rebalancing boosts production of short‑chain fatty acids (acetate, propionate, butyrate), which serve as energy sources for colonocytes, tighten tight‑junction complexes (ZO‑1, occludin, claudin‑1), and signal through G‑protein‑coupled receptors to dampen NF‑κB‑mediated cytokine storms. Across DSS‑induced colitis models, polysaccharide supplementation consistently lowers IL‑1β, TNF‑α, and IL‑6, translating into reduced disease activity scores.

The therapeutic promise extends beyond the lab. Food manufacturers and nutraceutical firms can leverage these insights to formulate functional ingredients that meet growing consumer demand for gut‑health solutions. Clinical translation will require dose‑standardization, safety profiling, and integration with existing IBD treatment algorithms. As regulatory pathways for dietary interventions evolve, polysaccharide‑based products could capture a sizable share of the $10 billion global IBD therapeutics market, offering patients a safer, cost‑effective complement to conventional drugs.